Sernova, Seraxis agree to merge to form BetaNova Biotherapeutics

PUBT · 2d ago
Sernova, Seraxis agree to merge to form BetaNova Biotherapeutics
  • Sernova Biotherapeutics agreed on Sept. 8, 2026 to merge with Seraxis Holdings to form BetaNova Biotherapeutics.
  • Transaction combines both companies’ diabetes technologies around islet cell replacement, targeting a differentiated approach to type 1 diabetes.
  • Completion remains subject to shareholder approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100700PRIMZONEFULLFEED9824261) on September 10, 2026, and is solely responsible for the information contained therein.